Curis, Inc. · NASDAQ:CRIS

Curis — Investor Presentation (December 2022)

23 slides from Curis's investor presentation, December 2022

  1. Slide 1: Corporate Presentation

    Corporate Presentation NASDAQ: CRIS

  2. Slide 2: Cautionary Note Regarding Forward Looking Statements

    Cautionary Note Regarding Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “expect(s),” “believe(s),” “will,”

  3. Slide 3: Corporate Overview

    Corporate Overview Summary Investment Curis develops novel cancer therapeutics in areas of significant unmet patient need Thesis Cash runway into 2025 – $98.7M as of Sept 30, 2022 Emavusertib is positioned to become the cornerstone agent in heme malignancies Lead • IRAK4-L is the most prevalent driv

  4. Slide 4: Pipeline

    Pipeline Curis develops first-in-class cancer therapeutics PRE-CLINICAL CLINICAL MARKETED Dose Clinical Indication Proof of Principle Safety Pivotal Commercial Optimization Activity Heme Malignancies Lead Program emavusertib* IRAK4-driven Leukemia • Potential best-in-class, as the only IRAK4 inhibit

  5. Slide 5: Emavusertib: Overview of Initial Clinical Data

    Emavusertib: Overview of Initial Clinical Data

  6. Slide 6: Emavusertib Overview

    Emavusertib Overview Initial clinical data support development strategy for novel IRAK4 inhibitor with targeted mutations all comers Monotherapy Patients, Grouped by Mutation Status Monotherapy Combination 24 patients 34 patients with targeted mutation without targeted mutation BTK-naïve BTK-experie

  7. Slide 7: IRAK4 Biology and Mechanism of Action

    IRAK4 Biology and Mechanism of Action

  8. Slide 8: Emavusertib Mechanism of Action

    Emavusertib Mechanism of Action IRAK4 is a novel and important target across multiple heme malignancies IRAK4 in AML/MDS IRAK4 in NHL/CLL Spliceosome mutation drives overexpression of IRAK4-L TLR Pathway is dependent upon IRAK4 for function (which causes constitutive activation of the myddosome) (2n

  9. Slide 9: Emavusertib Unique Molecular Fingerprint

    Emavusertib Unique Molecular Fingerprint The NCI has selected emavusertib Targeted design specifically engineered to hit key oncogenic targets for both clinical and non-clinical studies of IRAK4 inhibition Emavusertib Emavusertib in oncology Kinase Interaction Map Binding Affinity Target Kd nM NCI S

  10. Slide 10: Emavusertib Preclinical Data

    Emavusertib Preclinical Data Clear anti-cancer activity suggests broad potential across heme malignancies AML/MDS AML/MDS NHL/CLL Monotherapy Combination Therapy Combination Therapy vehicle Vehicle Mean Tumor Volume (mm3) ± SEM Relative Cell Growth ibrutinib reduction of emavusertib leukemic blasts

  11. Slide 11: Emavusertib in Leukemia (AML/MDS)

    Emavusertib in Leukemia (AML/MDS)

  12. Slide 12: Emavusertib in AML/MDS with FLT3 Mutation

    Emavusertib in AML/MDS with FLT3 Mutation Preclinical data suggest potential to address FLT3 population, as well as spliceosome population “Concomitant targeting of IRAK1 or IRAK4, alongside FLT3, is the most effective means to overcome the adaptive resistance incurred when targeting FLT3” IRAK acti

  13. Slide 13: Emavusertib Initial Clinical Data

    Emavusertib Initial Clinical Data Potential for clear regulatory path in two target populations: AML FLT3 and AML Spliceosome CR/CRh Rate FLT3 AML 2/7 (29%) Best Percent Change in Bone Marrow Blast from Baseline Spliceosome AML 2/9 (22%) • All patients were R/R, most patients received prior HMA 1 o

  14. Slide 14: Emavusertib Initial Clinical Data

    Emavusertib Initial Clinical Data Clear unmet need in R/R hrMDS – there are no approved therapies ORR Spliceosome MDS 5/11 (45%) • All patients on study were R/R, most patients received prior HMA 1 o Prognosis for this population is very poor; mOS is 4-6 months o There are no approved therapies for

  15. Slide 15: Genomic data provide clear rationale for monotherapy and combination

    Emavusertib in AML/MDS Genomic data provide clear rationale for monotherapy & combination Rationale for Rationale for Monotherapy Combination IRAK4-L is the most prevalent disease driver IRAK4-L is heavily expressed in IRAK4-L is expressed at some level 1,2 800 in AML/MDS > 50% of all AML/MDS patien

  16. Slide 16: Emavusertib in AML/MDS

    Emavusertib in AML/MDS Clinical data support strategy for monotherapy & combination Initial Clinical Data in AML/MDS (patients treated with monotherapy, grouped by mutation status) In patients with a targeted mutation: o Enhanced monotherapy efficacy in a genetically-defined population suggests pote

  17. Slide 17: Emavusertib in Leukemia (AML/MDS)

    Emavusertib in Leukemia (AML/MDS) The ideal candidate to address the two largest genetically-defined populations in AML/MDS Emavusertib addresses the two largest genetically-defined populations in AML/MDS: 1 1) IRAK4-L (>50% of population) Next Steps 2 2) FLT3 (>25% of population) TakeAim Leukemia S

  18. Slide 18: Emavusertib in Lymphoma (NHL/CLL)

    Emavusertib in Lymphoma (NHL/CLL)

  19. Slide 19: Emavusertib in B Cell Cancers

    Emavusertib in B Cell Cancers Combination therapy provides complimentary inhibition of two pathways that drive NF-κB NFκB Biology: Two Pathways Drive B Cell Cancers Clinical Strategy: Use Combination Therapy BCR and TLR Pathways independently drive NF-κB overactivity In preclinical testing, blocking

  20. Slide 20: Emavusertib Initial Clinical Data

    Emavusertib Initial Clinical Data Majority of patients achieved decreases in tumor burden, including complete responses NHL/CLL combination with ibrutinib Change in Tumor Burden Over Time 100% 80% % Change in Tumor Burden from Baseline 60% 40% BTK-naïve 20% BTK-experienced 0% 0 50 100 150 200 250 30

  21. Slide 21: Emavusertib in Lymphoma (NHL/CLL)

    Emavusertib in Lymphoma (NHL/CLL) The ideal candidate to combine with BTKi to maximize downregulation of NF-κB • Patients are currently treated with BTKi because it downregulates NF-κB • Two pathways drive NF-κB: Next Steps 1) BCR Pathway: addressed by blocking BTK TakeAim Lymphoma Study 2) TLR Path

  22. Slide 22: Corporate Overview

    Corporate Overview Summary Investment Curis develops novel cancer therapeutics in areas of significant unmet patient need Thesis Cash runway into 2025 – $98.7M as of Sept 30, 2022 Emavusertib is positioned to become the cornerstone agent in heme malignancies Lead • IRAK4-L is the most prevalent driv

  23. Slide 23: End of Corporate Presentation

    End of Corporate Presentation NASDAQ: CRIS

Curis — Investor Presentation (December 2022) on 6ix